Millie
your market intelligence analyst
Search Results
33 results
Your search is now limited to «Diabetes Clinical Trials» expert search.
FeedNavigator (EU) 09/17/2019 10:07
Table 9 Multifactorial logistic regression analysis of occurrence of vision-threatening diabetic retinopathy among all diabetic patients Questionnaire The participants with DM completed a questionnaire for lifestyle and medical conditions, and the content and results of the questionnaire are summarised in online supplementary file 2.
FeedNavigator (EU) 09/17/2019 08:02
J Gerontol A Biol Sci Med Sci. 2018 Oct 8;73(11):1560-1567. doi: 10.1093/gerona/gly124. Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
Business Wire 09/17/2019 06:05
LA ROCHELLE, Francia--(BUSINESS WIRE)--VALBIOTIS (París: ALVAL) (FR0013254851- elegible para ALVAL/PEA/SME), una compañía de investigación y desarrollo comprometida con la innovación científica para prevenir y combatir enfermedades metabólicas, ha anunciado hoy la presentación de un estudio preclínico realizado por el laboratorio CarMeN sobre el principio activo TOTUM-63, en el contexto del 55º Congreso anual de la Asociación Europea para el Estudio de la Diabetes, que se celebrará en Barcelona.
Business Wire 09/16/2019 23:54
LA ROCHELLE, Frankreich--(BUSINESS WIRE)--Pflichtmitteilung: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von Stoffwechselkrankheiten verschrieben hat, kündigte heute die Präsentation einer präklinischen Studie des CarMeN-Labors über den Wirkstoff TOTUM-63 auf der 55.
Business Wire 09/16/2019 15:48
LA ROCHELLE, Francia--(BUSINESS WIRE)--VALBIOTIS (Paris:ALVAL) (FR0013254851 – ammissibile per ALVAL / PEA/SME), una società di Ricerca e Sviluppo impegnata nell’innovazione scientifica per prevenire e combattere le malattie del metabolismo, oggi ha annunciato la presentazione di uno studio preclinico condotto dal laboratorio CarMeN sul principio attivo TOTUM-63, nell’ambito della 55a edizione del Congresso annuale della European Association for the Study of Diabetes che si svolgerà a Barcellon.
Business Wire 09/16/2019 11:40
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News : VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / éligible PEA/PME), entreprise de Recherche & Développement engagée dans l’innovation scientifique, pour la prévention et la lutte contre les maladies métaboliques, annonce la présentation d’une étude préclinique réalisée par le laboratoire CarMeN sur la substance active TOTUM-63 au 55e congrès de l’European Association for the Study of Diabetes, du 16 au 20 septembre 2019 à Barcelone (Esp.
Business Wire 09/16/2019 11:40
The results of the Phase IIA international randomized, placebo-controlled study showed that in patients with prediabetes, TOTUM-63 reduces fasting blood glucose and blood glucose at 2 hours, two risk factors of type 2 diabetes.

Personal Care

Household Products

Business Issues

Trends

Companies - Public

Companies - Venture Funded

Information Technologies

Regions

Job Titles